30 December 2020
: Case report
Valproic Acid-Induced Thrombocytopenia-Related Spontaneous Systemic Bleeding
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Adverse events of drug therapy
Jackie P. Johnston12ABCDEF*, Steven F. Nerenberg12CDEFDOI: 10.12659/AJCR.927830
Am J Case Rep 2020; 21:e927830
Abstract
BACKGROUND: Valproic acid is utilized for the management of various disease states, but coagulation changes, such as thrombocytopenia, can limit use. Valproic acid is a highly protein-bound drug. Serum levels of 50–100 mcg/mL are considered therapeutic, with minimal risk of toxicity when maintained within the recommended therapeutic index. We present a case of valproic acid-induced thrombocytopenia associated with spontaneous systemic bleeding.
CASE REPORT: A 57-year-old woman with history of generalized anxiety disorder and choreiform movements presented to the Emergency Department with 1 day of oral and vaginal bleeding. The patient had been started on valproic acid for choreiform movements 3 weeks prior. On physical exam, the patient was noted to have atraumatic contusions and ecchymosis. A CT head revealed left temporal frontal subdural hematoma (4.5 mm), acute subdural hematoma along the posterior aspect of the interhemispheric falx (5 mm), mass effect on the right lateral ventricle, and an approximately 3 mm right-to-left midline shift. Laboratory testing was notable for platelets 4000/μL, hemoglobin 7.3 g/dL, hematocrit 23.1%, fibrinogen 467 mg/dL, and valproic acid random level 26.3 μg/mL. Thromboelastography releveled normal values except for a decreased maximum amplitude of 33.4 mm.
CONCLUSIONS: Although the clinical relevance is still debated, few case reports of significant bleeding related to valproic acid-induced thrombocytopenia exist. To the best of our knowledge, this is the first case report of spontaneous systemic bleeding due to valproic acid-induced thrombocytopenia in the setting of normal fibrinogen levels. Furthermore, this report demonstrates the potential risk of thrombocytopenia with subtherapeutic VPA levels.
Keywords: Bleeding Time, Thrombocytopenia, Valproic Acid, Anemia, Hemorrhage, Middle Aged
1248 50
In Press
09 Jun 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939250
08 Jun 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939098
06 Jun 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.940200
05 Jun 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939421
Most Viewed Current Articles
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
07 Dec 2021 : Case report
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250